Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index; 7 of the 12 sources its claims cite were checked for support.

SUVmax-IPI as a New Prognostic Index in Metastatic Non-Small Cell Lung Cancer Patients Receiving Nivolumab

Open access

Abstract

Multicenter retrospective analysis combining SUVmax with inflammatory markers into a prognostic index for metastatic NSCLC.

Overview

CoChat Summary

TL;DR

This multicenter retrospective study of 187 metastatic NSCLC patients treated with nivolumab found that a composite score, SUVmax-IPI, was independently associated with overall survival but not progression-free survival. The score outperformed SUVmax alone and showed better fit than IPI alone, but its discrimination was modest and the cutoff needs external validation.

Key findings

  • In 187 patients, the optimal SUVmax-IPI cutoff was 241.9; 65.2% of patients were at or below this threshold and 34.8% were above it.
  • Patients with SUVmax-IPI > 241.9 had shorter overall survival than those with SUVmax-IPI ≤ 241.9: median OS 15 vs 35 months (log-rank p = 0.002); 1-year OS 58.6% vs 78.3% and 2-year OS 29.8% vs 54.5%.
  • SUVmax-IPI was not significantly associated with progression-free survival: median PFS 8.0 vs 15.0 months (log-rank p = 0.175).
  • In multivariable analysis, SUVmax-IPI > 241.9 remained an independent predictor of OS (HR 2.50; 95% CI 1.39–4.49; p = 0.002), while the model’s discrimination was modest (OS C-index 0.583; PFS C-index 0.525).
  • Compared with its components, SUVmax alone was not significantly associated with OS (HR 1.06; p = 0.805), while SUVmax-IPI was significant in both univariate and multivariate analyses (HR 1.96; p = 0.002; multivariate HR 1.97; p = 0.032).

Methods

  • Multicenter retrospective study across 5 tertiary hospitals in Turkey, including 187 consecutive patients with histologically confirmed metastatic NSCLC treated with nivolumab between May 2019 and December 2024; eligibility required age ≥18, ≥3 months of nivolumab, and available post-treatment FDG-PET and laboratory data.
  • SUVmax was taken from pretreatment FDG-PET, IPI was calculated as (CRP × NLR)/albumin, and SUVmax-IPI was defined as SUVmax × IPI; an ROC analysis with Youden’s index set the cutoff at 241.9.
  • Survival was analyzed using Kaplan–Meier/log-rank testing and univariable/multivariable Cox regression; the paper also reports time-dependent AUC, Harrell’s C-index, calibration, landmark analyses at 2 and 3 months, decision curve analysis, and comparisons against LIPI, NLR, PLR, and SII.

Limitations

  • The authors state that the study is retrospective, the cutoff was derived within the same cohort and may be overfit, and external validation is required before clinical use.
  • The authors state that requiring at least 3 months of nivolumab limits generalizability to patients who discontinue earlier.
  • Evident from the text: discrimination was modest (e.g., OS AUC 0.368 at 12 months and 0.337 at 24 months; PFS AUC 0.443 and 0.395), which suggests limited predictive performance despite statistical significance.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/curroncol32100566

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Kaplan–Meier Analysis of Progression-Free Survival (a) and Overall Survival (b) with Nivolumab Treatment.
Figure 1 Kaplan–Meier Analysis of Progression-Free Survival (a) and Overall Survival (b) with Nivolumab Treatment.CC BY · PubMed Central
Figure 2 Kaplan–Meier Survival Analysis of Overall Survival in Nivolumab-Treated Patients: SUVmax IPI > 241.9 versus ≤241.9.
Figure 2 Kaplan–Meier Survival Analysis of Overall Survival in Nivolumab-Treated Patients: SUVmax IPI > 241.9 versus ≤241.9.CC BY · PubMed Central
Figure 3 Kaplan–Meier Analysis of Progression-free Survival in Nivolumab-Treated Patients: SUVmax-IP1 > 241.9 versus ≤241.9.
Figure 3 Kaplan–Meier Analysis of Progression-free Survival in Nivolumab-Treated Patients: SUVmax-IP1 > 241.9 versus ≤241.9.CC BY · PubMed Central

Verification

Claims the paper makes

6 Valid · 0 Not valid · 4 Not checked · 30 Own results and interpretations

8 more claims

Create a free account to see all 40 claims and to verify the 1 reference still open.

See all claims — free account
  • Probably not a substantial claim. 13
  • It may state two separate claims as one. 16

Create a free account to see these claims.

Citations

Cites

Show all 19 references

Research works printed but not linked: 2

  1. Tomita, 2018, Inflammatory Prognostic Index in Resected NSCLC, Asian Pac. J. Cancer Prev., 19, 2867
  2. Jin, 2016, Prognostic Value of the Standardized Uptake Value Maximum Change Calculated by Dual-Time-Point (18F)-Fluorodeoxyglucose PET Imaging in Patients with Advanced NSCLC, OncoTargets Ther., 9, 2993

Cited by

See all 2

Metadata

Authors
Kolkıran, N., Erdoğan, A. P., Şahbazlar, M., Taş, S., Gököz Doğu, G., Canaslan, K., Ünek, İ. T., Demirkıran, Ö., Demir, B., Teküstün, G. N., Tanrıverdi, Ö., & Ekinci, F.
Affiliations
  • Manisa Celal Bayar University (TR)
  • Pamukkale University (TR)
  • Department of Medical Oncology, Faculty of Medicine, Pamukkale University, Denizli 20070, Turkey
  • Dokuz Eylül University (TR)
  • Adnan Menderes University (TR)
  • Muğla University (TR)
Corresponding author
Kolkıran, Nagihan
Venue
Current Oncology
Publisher
MDPI AG
Published
2025-10-09
Volume
32
Issue
10
Pages
566
ISSN
  • 1198-0052 (ISSN-L)
  • 1718-7729
OpenAlex
W4414989296
Cited by
2
References
19
Citations by year
2026: 1 · 2025: 1
FWCI
0.82
Type
journal article
Language
en
Open access
Locations
  • Current Oncology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Manisa Celal Bayar Üniversitesi
Topics
  • Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords
metastatic non-small cell lung cancer, nivolumab, prognostic score, SUVmax, FDG-PET, systemic inflammatory markers, overall survival, progression-free survival, immune checkpoint therapy
MeSH terms
Antineoplastic Agents, Immunological, Nivolumab, Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Metastasis, Prognosis, Retrospective Studies, Fluorodeoxyglucose F18, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SUVmax-IPI as a New Prognostic Index in Metastatic Non-Small Cell Lung Cancer Patients Receiving Nivolumab. https://app.cochat.ai/papers/10.3390/curroncol32100566
The paper
Kolkıran, N., Erdoğan, A. P., Şahbazlar, M., Taş, S., Gököz Doğu, G., Canaslan, K., Ünek, İ. T., Demirkıran, Ö., Demir, B., Teküstün, G. N., Tanrıverdi, Ö., & Ekinci, F. (2025). SUVmax-IPI as a New Prognostic Index in Metastatic Non-Small Cell Lung Cancer Patients Receiving Nivolumab. Current Oncology. https://doi.org/10.3390/curroncol32100566

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.